drugset
drugset / Trial / NCT04808154

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.

NCT04808154 ↗

Phase 1 Completed 28 enrolled Sinew Pharma Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability and Pharmacokinetic profile of SNP-630 when oral administered to healthy subjects.

Timeline

Start
2021-07-22
Primary completion
2021-08-31
Completion
2021-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SNP-630 Unknown 720 mg Oral

Indications

metabolic dysfunction-associated steatohepatitis